Arch Biopartners Inc. (ACHFF)
USD 1.1
(-7.56%)
USD 1.1
(-7.56%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.18 Million CAD | 7.13% |
| 2022 | 3.9 Million CAD | -17.16% |
| 2021 | 4.71 Million CAD | 72.31% |
| 2020 | 2.73 Million CAD | 10.14% |
| 2019 | 2.48 Million CAD | 164.64% |
| 2018 | 938.93 Thousand CAD | 205.97% |
| 2017 | 306.86 Thousand CAD | 135.38% |
| 2016 | 130.37 Thousand CAD | 144.56% |
| 2015 | -292.54 Thousand CAD | -2413.49% |
| 2014 | -11.63 Thousand CAD | -103.14% |
| 2013 | 370.55 Thousand CAD | 616.48% |
| 2012 | -71.74 Thousand CAD | 65.1% |
| 2011 | -205.56 Thousand CAD | 59.39% |
| 2010 | -506.24 Thousand CAD | -31739.56% |
| 2009 | -1590.00 CAD | -100.1% |
| 2008 | 1.64 Million CAD | 21.43% |
| 2007 | 1.35 Million CAD | 45.57% |
| 2006 | 928.52 Thousand CAD | -12.28% |
| 2005 | 1.05 Million CAD | -6.22% |
| 2004 | 1.12 Million CAD | 85.65% |
| 2003 | 607.98 Thousand CAD | -25.23% |
| 2002 | 813.16 Thousand CAD | 595.89% |
| 2001 | 116.85 Thousand CAD | 265.92% |
| 2000 | -70.42 Thousand CAD | -22117.03% |
| 1999 | -317.00 CAD | 25.24% |
| 1998 | -424.00 CAD | 90.79% |
| 1997 | -4604.00 CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 4.94 Million CAD | 4.54% |
| 2024 Q3 | 5.28 Million CAD | 6.69% |
| 2024 Q1 | 4.73 Million CAD | 13.12% |
| 2023 FY | 4.18 Million CAD | 7.13% |
| 2023 Q4 | 4.18 Million CAD | 16.86% |
| 2023 Q1 | 4.23 Million CAD | 8.32% |
| 2023 Q3 | 3.58 Million CAD | -31.31% |
| 2023 Q2 | 5.21 Million CAD | 23.2% |
| 2022 Q1 | 3.67 Million CAD | -22.03% |
| 2022 FY | 3.9 Million CAD | -17.16% |
| 2022 Q4 | 3.9 Million CAD | 2.74% |
| 2022 Q2 | 3.62 Million CAD | -1.3% |
| 2022 Q3 | 3.8 Million CAD | 4.77% |
| 2021 Q2 | 3.26 Million CAD | 16.37% |
| 2021 Q3 | 5.58 Million CAD | 70.87% |
| 2021 Q4 | 4.71 Million CAD | -15.49% |
| 2021 FY | 4.71 Million CAD | 72.31% |
| 2021 Q1 | 2.8 Million CAD | 2.54% |
| 2020 Q3 | 2.01 Million CAD | -36.35% |
| 2020 Q4 | 2.73 Million CAD | 35.61% |
| 2020 FY | 2.73 Million CAD | 10.14% |
| 2020 Q2 | 3.17 Million CAD | 11.4% |
| 2020 Q1 | 2.84 Million CAD | 14.54% |
| 2019 Q2 | 1.86 Million CAD | 55.82% |
| 2019 Q1 | 1.19 Million CAD | 27.63% |
| 2019 Q3 | 2.08 Million CAD | 11.74% |
| 2019 Q4 | 2.48 Million CAD | 19.09% |
| 2019 FY | 2.48 Million CAD | 164.64% |
| 2018 Q3 | 158.14 Thousand CAD | 22.11% |
| 2018 FY | 938.93 Thousand CAD | 205.97% |
| 2018 Q4 | 938.93 Thousand CAD | 493.73% |
| 2018 Q2 | 129.5 Thousand CAD | -80.92% |
| 2018 Q1 | 678.89 Thousand CAD | 121.23% |
| 2017 Q4 | 306.86 Thousand CAD | 1.59% |
| 2017 FY | 306.86 Thousand CAD | 135.38% |
| 2017 Q1 | 277.5 Thousand CAD | 112.86% |
| 2017 Q2 | 52.74 Thousand CAD | -80.99% |
| 2017 Q3 | 302.06 Thousand CAD | 472.7% |
| 2016 FY | 130.37 Thousand CAD | 144.56% |
| 2016 Q4 | 130.37 Thousand CAD | 245.47% |
| 2016 Q2 | 61.72 Thousand CAD | 159.64% |
| 2016 Q1 | -103.5 Thousand CAD | 64.62% |
| 2016 Q3 | -89.62 Thousand CAD | -245.19% |
| 2015 Q2 | -556.46 Thousand CAD | -786.94% |
| 2015 Q1 | 81 Thousand CAD | 796.0% |
| 2015 Q4 | -292.54 Thousand CAD | 25.03% |
| 2015 FY | -292.54 Thousand CAD | -2413.49% |
| 2015 Q3 | -390.19 Thousand CAD | 29.88% |
| 2014 FY | -11.63 Thousand CAD | -103.14% |
| 2014 Q4 | -11.63 Thousand CAD | -106.34% |
| 2014 Q3 | 183.45 Thousand CAD | 63.44% |
| 2014 Q1 | 22.58 Thousand CAD | -93.9% |
| 2014 Q2 | 112.24 Thousand CAD | 396.93% |
| 2013 Q3 | 384.81 Thousand CAD | 3.55% |
| 2013 Q4 | 370.55 Thousand CAD | -3.71% |
| 2013 Q1 | -23.8 Thousand CAD | 66.82% |
| 2013 Q2 | 371.62 Thousand CAD | 1660.91% |
| 2013 FY | 370.55 Thousand CAD | 616.48% |
| 2012 Q4 | -71.74 Thousand CAD | 50.01% |
| 2012 Q1 | -135.18 Thousand CAD | 34.24% |
| 2012 Q2 | -93.13 Thousand CAD | 31.11% |
| 2012 Q3 | -143.53 Thousand CAD | -54.11% |
| 2012 FY | -71.74 Thousand CAD | 65.1% |
| 2011 FY | -205.56 Thousand CAD | 59.39% |
| 2011 Q4 | -205.56 Thousand CAD | 31.4% |
| 2011 Q3 | -299.65 Thousand CAD | 14.35% |
| 2011 Q2 | -349.85 Thousand CAD | 24.57% |
| 2011 Q1 | -463.82 Thousand CAD | 8.38% |
| 2010 Q2 | -87.00 CAD | 94.53% |
| 2010 FY | -506.24 Thousand CAD | -31739.56% |
| 2010 Q1 | -1590.00 CAD | 86.17% |
| 2010 Q3 | -640.18 Thousand CAD | -735745.98% |
| 2010 Q4 | -506.24 Thousand CAD | 20.92% |
| 2009 Q4 | -11.5 Thousand CAD | -1043.14% |
| 2009 FY | -1590.00 CAD | -100.1% |
| 2009 Q1 | 1.64 Million CAD | -47.92% |
| 2009 Q2 | 1.18 Million CAD | -27.54% |
| 2009 Q3 | -1006.00 CAD | -100.08% |
| 2008 Q4 | 3.15 Million CAD | 34.7% |
| 2008 Q1 | 1.35 Million CAD | -21.75% |
| 2008 Q2 | 1.98 Million CAD | 46.61% |
| 2008 FY | 1.64 Million CAD | 21.43% |
| 2008 Q3 | 2.33 Million CAD | 18.07% |
| 2007 FY | 1.35 Million CAD | 45.57% |
| 2007 Q4 | 1.72 Million CAD | 73.5% |
| 2007 Q3 | 995.57 Thousand CAD | 4.47% |
| 2007 Q2 | 953.02 Thousand CAD | 2.64% |
| 2007 Q1 | 928.52 Thousand CAD | -12.8% |
| 2006 FY | 928.52 Thousand CAD | -12.28% |
| 2006 Q4 | 1.06 Million CAD | 14.64% |
| 2006 Q3 | 928.84 Thousand CAD | -6.63% |
| 2006 Q2 | 994.81 Thousand CAD | -6.02% |
| 2006 Q1 | 1.05 Million CAD | 1.17% |
| 2005 Q4 | 1.04 Million CAD | 14.41% |
| 2005 Q2 | 1.01 Million CAD | -9.74% |
| 2005 Q1 | 1.12 Million CAD | -3.28% |
| 2005 FY | 1.05 Million CAD | -6.22% |
| 2005 Q3 | 914.56 Thousand CAD | -10.23% |
| 2004 Q2 | 823.09 Thousand CAD | 35.38% |
| 2004 Q1 | 607.98 Thousand CAD | 1066731.58% |
| 2004 FY | 1.12 Million CAD | 85.65% |
| 2004 Q4 | 1.16 Million CAD | -5.97% |
| 2004 Q3 | 1.24 Million CAD | 50.79% |
| 2003 Q4 | -57.00 CAD | 99.77% |
| 2003 FY | 607.98 Thousand CAD | -25.23% |
| 2003 Q1 | 813.16 Thousand CAD | 1540.7% |
| 2003 Q2 | -22.00 CAD | -100.0% |
| 2003 Q3 | -25.26 Thousand CAD | -114718.18% |
| 2002 Q1 | 116.85 Thousand CAD | 0.0% |
| 2002 Q4 | 49.56 Thousand CAD | 5.32% |
| 2002 FY | 813.16 Thousand CAD | 595.89% |
| 2002 Q3 | 47.05 Thousand CAD | 298.69% |
| 2002 Q2 | -23.68 Thousand CAD | -120.27% |
| 2001 Q2 | -49.19 Thousand CAD | 30.15% |
| 2001 Q3 | -22.71 Thousand CAD | 53.83% |
| 2001 FY | 116.85 Thousand CAD | 265.92% |
| 2001 Q1 | -70.42 Thousand CAD | 0.0% |
| 2000 Q1 | -317.00 CAD | 0.0% |
| 2000 FY | -70.42 Thousand CAD | -22117.03% |
| 1999 FY | -317.00 CAD | 25.24% |
| 1999 Q1 | -424.00 CAD | 87.62% |
| 1998 Q3 | -6780.00 CAD | -2012.15% |
| 1998 Q2 | -321.00 CAD | 0.0% |
| 1998 FY | -424.00 CAD | 90.79% |
| 1998 Q4 | -3425.00 CAD | 49.48% |
| 1997 FY | -4604.00 CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 73.451% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -1.624% |
| SQZ Biotechnologies Company | -36.23 Million USD | 111.548% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 90.221% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 166.38% |
| Mesoblast Limited | 55.85 Million USD | 92.508% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -351.357% |
| Genus plc | 190.6 Million USD | 97.804% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -87.175% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -244.753% |
| Marizyme, Inc. | 18.56 Million USD | 77.463% |
| ContraFect Corporation | -6.02 Million USD | 169.448% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -515.429% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -3008.249% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -262.196% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -86.641% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 23.937% |
| MultiCell Technologies, Inc. | 90.04 USD | -4647739.849% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 670.169% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 67.674% |
| EV Biologics, Inc. | 1.36 Million USD | -205.921% |
| Q BioMed Inc. | 4.06 Million USD | -3.077% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 86.303% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -572.422% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -315.287% |
| Biomind Labs Inc. | 711.4 Thousand USD | -488.263% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 96.189% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 67.322% |
| Skye Bioscience, Inc. | -5.72 Million USD | 173.145% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -386.482% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -2893.416% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 25.909% |
| IMV Inc. | 7.67 Million USD | 45.442% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -20964.655% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -90.052% |
| GB Sciences, Inc. | 1.74 Million USD | -139.505% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 2377.034% |
| HST Global, Inc. | 96.79 Thousand USD | -4223.572% |
| CSL Limited | 10.52 Billion USD | 99.96% |
| Halberd Corporation | 144.72 Thousand USD | -2791.712% |
| Enzolytics Inc. | 981.65 Thousand USD | -326.312% |
| Resverlogix Corp. | 6.45 Million USD | 35.128% |
| Affymax, Inc. | -5.59 Million USD | 174.771% |
| SYBLEU INC | 473.71 Thousand USD | -783.426% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 721.748% |
| argenx SE | -2.02 Billion USD | 100.206% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 90.365% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 108.902% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -54.504% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 147.341% |
| AVAX Technologies, Inc. | -5.9 Million USD | 170.892% |
| Zenith Capital Corp. | 10.06 Thousand USD | -41483.019% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.394% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -1987.948% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -75.392% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -2443.882% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 93.088% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -109.309% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 262.835% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1063.414% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 79.36% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 22945.917% |
| BioStem Technologies, Inc. | 4.47 Million USD | 6.42% |
| ONE Bio Corp. | 9.04 Million USD | 53.707% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -1979.42% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 319559.16% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -1929.374% |
| Agentix Corp. | 37.63 Thousand USD | -11020.924% |
| LadRx Corporation | -2.03 Million USD | 305.499% |
| Cell Source, Inc. | 9.23 Million USD | 54.669% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 20606.248% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -558.868% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -558.868% |
| NovAccess Global Inc. | 2.17 Million USD | -92.104% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 40.816% |
| Itoco Inc. | 228.3 Thousand USD | -1733.037% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -2977.392% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 15.576% |
| Kadimastem Ltd | -253.1 Thousand USD | 1753.45% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -941.415% |
| CytoDyn Inc. | 20.26 Million USD | 79.346% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 646918.393% |
| Mobile Lads Corp. | 484.23 Thousand USD | -764.238% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 45252.8% |
| Qrons Inc. | 351.42 Thousand USD | -1090.835% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 45.693% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 1776.514% |
| Rebus Holdings, Inc. | 305 Thousand USD | -1272.103% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 6.105% |
| International Stem Cell Corporation | 2.59 Million USD | -61.58% |
| Bioxytran, Inc. | 1.89 Million USD | -120.385% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -6605.198% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -91.889% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -21.867% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 51.071% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -441.662% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 434.793% |
| Neutra Corp. | 52.18 Thousand USD | -7919.076% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 268.136% |
| PureTech Health plc | -167.19 Million USD | 102.503% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 1808.77% |
| IXICO plc | -4.44 Million USD | 194.158% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 68.342% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 92.37% |
| CSL Limited | 10.52 Billion USD | 99.96% |
| Cellectis S.A. | -43.81 Million USD | 109.55% |